Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy
Administering natalizumab subcutaneously rather than intravenously to treatment-eligible patients would result in administration time and cost savings thus determining a favorable impact for the MS center, the patient and the society.
Authors
- Daria Perini
- Marco Vercellino (ORCID: https://orcid.org/0000-0002-4199-3884)
- Lorenzo Pradelli (ORCID: https://orcid.org/0000-0002-7648-8917)
- Luca Prosperini (ORCID: https://orcid.org/0000-0003-3237-6267)
- Salvatore Cottone
- Laura Santoni
Institutions
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Carlo Forlanini Hospital (IT)
- Center for Outcomes Research and Clinical Epidemiology (IT)
- Biogen (Italy) (IT)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ceor.s501716
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen